Scientific review article summarizes PExA’s technology

This is a Google translated news text!

In a recently published review article, University Hospital and University of Southampton researchers evaluate PExA's technology by summarizing the results of a number of previously published studies based on samples from PExA and other comparable methods.

In the article, the researchers describe, among other things, how acute and chronic lung diseases are increasing more than many other diseases and that they now account for a significant proportion of the morbidity and mortality seen among adults worldwide.

It is further described how the small airways, which are the deepest part of the lung, play a crucial role in the development of many of these lung diseases and that there is a great need for new and non-invasive methods to study this particular region.

Furthermore, it is stated that PExA's technology offers unique and important advantages compared to other available methods in that it is non-invasive and enables a sample directly from the small airways. It also emphasizes the importance of progress in recent publications that demonstrate that it is possible to study the molecular composition of PEx samples and how PExA thus has the potential to play an important role in the development of future healthcare.

The article with the title: "Particles in Exhaled Air (PExA): Clinical Uses and Future Implications" is publicly available via the PubMed link: www.ncbi.nlm.nih.gov/pmc/articles/PMC11119244.

Tomas Gustafsson, CEO at PExA comments:

• We are very happy that the research group in Southampton, which has been a customer of PExA since 2022, has chosen to make a review article in which they compile the state of scientific knowledge around our product. This type of independent publication describing PExA's technology has high credibility and appeals to the customer category of lung scientists around the world that we cater to. The fact that it also describes our technology in very positive terms makes the article the best possible marketing for the Company. This together with increased exposure at international congresses in the past year means that we look forward to how this article further contributes to good conditions for increased use and a growing market for our technology.

For further information, please contact:

Tomas Gustafsson, E-mail: [email protected]

About PExA AB:

PExA AB (556956-9246) has developed the PExA 2.1, a patented research instrument that helps researchers intelligently collect biological samples from the smallest airways through a simple exhalation maneuver. PExA's technology is currently used by prominent research groups in several different countries and research with the instrument has resulted in approximately 50 scientific publications, which serve as reference material for PExA's method. The company's long-term goal is to market and sell diagnostic instruments for popular diseases (e.g. lung cancer and COPD) to be used globally for diagnosis or general screening at facilities where care is offered. The company intends at the time it is relevant to sell to clinics to have developed more patient-friendly, flexible and commercial products, which means that PExA addresses a significantly wider market, which today includes several million patients globally.

PExA's B share is listed on the Spotlight Stock Market.

Public link

Please use the above public link if you want to share this noodl on another website.